MedTrace Logo

Sildenafil in COVID-19

NCT04489446 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2021-09-29

No results posted yet for this study

Summary

This randomised trial aims to assess the role of sildenafil in improving oxygenation amongst hospitalised patients with COVID19.

Conditions

  • Covid19
  • SARS-COV2 Infection

Interventions

DRUG

Sildenafil

Patients allocated to this arm will receive Sildenafil 25mg every 8 hours orally for up to seven consecutive days.

DRUG

Placebo

Patients allocated to this arm will receive a matching placebo similar to Sildenafil pills used in the intervention arm. Placebos will be delivered orally every 8 hours for up to seven consecutive days.

Sponsors & Collaborators

  • Hospital Naval Almirante Nef, Viña del Mar, Chile

    collaborator UNKNOWN

  • Universidad Nacional Andres Bello

    lead OTHER

Principal Investigators

  • Mario Santamarina, MD · Hospital Naval Almirante Nef

  • Felipe Martinez, MD, MSc · Universidad Andres Bello

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-08-19
Primary Completion
2021-04-30
Completion
2021-06-30

Countries

  • Chile

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04489446 on ClinicalTrials.gov